PDCD1 and non-small cell lung carcinoma: For example, the KIR3DS1 genetic variant of KIR is significantly associated with resistance to PD-1 blockade and progression-free survival in patients with NSCLC, suggesting a potential role for NK cells in responding to PD-1 immunotherapy (Trefny et al., 2019).